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PRETREATMENT WITH IMATINIB MESYLATE INCREASES TRANSPLANT-
RELATED MORTALITY AFTER ALLOGENEIC TRANSPLANTATION
Zander, A.R.; Zabelina, T.; Renges, H.; Schieder, H.; Fehse, N. Uni-
versity Hamburg-Eppendorf, Hamburg, Hamburg, Germany.
Imatinib mesylate (IM) has excellent activity against chronic
myelogenous leukemia and Philadelphia-positive acute lympho-
blastic leukemia and is presently the preferred front-line treatment
for CML. Because of the effectiveness of IM, most patients will
receive an allogeneic bone marrow transplantation after failure
from IM. There is concern based on case reports that pretreatment
with IM might predispose to toxicity after transplantation. We
undertook a retrospective study of 23 patients who reveived IM
before transplantation and 23 historical controls without IM treat-
ment. There was a trend toward a higher incidence of acute
graft-versus-host disease (GvHD) II to IV in the IM group (P 
.07) and a signiﬁcantly higher incidence of severe GvHD III to IV
in the IM group (57% vs 17%; P  .006). The mean maximun
bilirubin was 5.4 in the IM group and 3.3 in the non-IM group.
Overall survival (OS) was 16% in the IM group and 48% in the
non-IM group (P  .03). Transplantation-related mortality
(TRM) was 74% in the IM group and 40% in the non-IM group
(P  .07). Discontinuation of IM at least 15 days before transplan-
tation decreased the TRM (P  .05) and led to a trend toward
improved OS (P  .09). Patients treated with IM suffered more
TRM, GvHD, and liver toxicity and had a poorer survival than
those who were not. Discontinuation of IM 2 weeks before trans-
plantation might decrease TRM. Larger studies are needed to
evalutate IM as a risk factor for a consecutive transplantation.
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CELLULAR IMMUNOTHERAPY UTILIZING LOW-DOSE IRRADIATION,
BONE MARROW TRANSPLANTATION. AND DONOR LYMPHOCYTE IN-
FUSIONS FOR ACUTE LEUKEMIA: A PHASE II STUDY
Colvin, G.A.1; Rathore, R.1; Lum, L.G.1; Abedi, M.1; Ballen, K.K.2;
Dey, B.R.2; Elfenbein, G.J.1; Quesenberry, P.J.1 1. Roger Williams
Medical Center, Adele R. Decof Cancer Center, Providence, RI; 2.
Massachusetts General Hospital, Boston, MA.
We previously studied allogeneic bone marrow transplantation
(BMT) with HLA-identical donors using 100 cGy as host condi-
tioning and infusing 1  108 CD3 cells/kg from nonmobilized
peripheral blood and achieved complete responses (CRs) in 4 of 11
refractory hematologic malignancy patients. Only 25% of those
eligible for allogeneic BMT have an HLA-identical sibling donor;
nearly 100% have HLA-3/6 or HLA-4/6 donors. We evaluated
CD3 cell dose escalation with transplantation in patients with
refractory malignancies. We performed a total of 44 HLA-mis-
matched transplants with escalation of the CD3 cell dose from
1  106 to 2  108 cells/kg using G-CSF primed PBSC, with a
conditioning regimen of 100 cGy TBI. Thirty patients have been
treated at the highest dose level. The CD34 cell dose averaged
2  106 cells/kg. Patient age ranged from 16 to 82 years. One
treatment-related death occurred from grade IV acute graft-ver-
sus-host disease. Most patients had a transient infusional haploim-
munostorm syndrome believed to be cytokine/immunologically
modulated. There were no objective responses in the 15 patients
with solid tumors. Of the 29 patients with hematologic malignan-
cies, 3 of 5 patients with NHL responded to treatment. Two
patients remain in CR and 29 and 37 months, and 1 patient is
in partial response (PR) with marrow-only disease at 34 months.
We observed several encouraging responses in patients with re-
fractory AML. We treated 15 patients with AML and have ob-
tained a durable CR in 3 of 12 and transient PR in 7 of 12 evaluable
patients. All responses occurred at CD3 levels of 1 to 2  108
cells/kg. CR occurred even after the loss of detectable donor
chimerism ( 5%). Donor cells labeled with indium111 analyzed 1,
2, 3, and 6 days after BMT in 1 patient showed persistent signal in
the bone marrow and spleen. Serial bone marrow biopsies per-
formed in several patients showed evidence of large tumor reduc-
tion and early resumption of hematopoiesis. The kinetics of donor
chimerism from patients show a majority of donors cells in
circulation3marrow at 24 hours and marrow3circulation at 48
hours. There was a loss of detectable chimerism by 6 days. In
summary, TBI of 100 cGy followed by HLA-mismatched trans-
plantation is a biologically active therapy for refractory AML and
NHL. This well-tolerated outpatient treatment produced minimal
toxicity for the majority of patients. Theories on biological effect
include an initial graft versus tumor cell kill, altered host immune
response breaking host tumor tolerance, persistent nondetectable
microchimerism, and any combination of these 3 mechanisms.
AUTOLOGOUS
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RITUXIMAB DOES NOT INHIBIT CHEMO-MOBILIZATION OF HPC OR
ENGRAFTMENT FOLLOWING AUTOLOGOUS TRANSPLANT FOR LYM-
PHOMA
Kaufman, J.L.; Lonial, S.; Hicks, M.; Langston, A.; Flowers, C.;
Lechowicz, M.J.; Khoury, H.; Waller, E.K. Winship Cancer Institute,
Emory University School of Medicine, Atlanta, GA.
Treatment for patients with relapsed non-Hodgkin’s lymphoma
(NHL) and Hodgkin’s lymphoma (HL) includes high-dose che-
motherapy and autologous hematopoietic progenitor cell (HPC)
transplant, but the role of rituximab (R) during mobilization of
autologous HPC is unknown. The addition of R may purge the
HPC graft of B cells but may impact negatively on mobilization or
engraftment. Methods: We performed a single institution IRB-
approved review of the effect R in the mobilization regimen in 80
patients with relapsed/refractory HL or NHL who underwent
chemomobilization of HPC followed by autologous transplant.
The study group included 32 patients with relapsed HL, 6 of who
had LPHL and expressed CD20 on their lymphoma cells, and 48
patients with relapsed or refractory NHL, of whom 32 had
CD20 lymphoma. Patients received chemotherapy with or with-
out R. Chemotherapy consisted of ICE (n  46, 25 with R),
HyperCVAD (n  14, 8 with R), single-agent cytoxan (n  9, 2
with R), VTEPA (n  4, 1 plus R), CHOP (n  3, 1 plus R), and
others (n  4, 1 with R). The conditioning regimens before
transplantation were Bu/CY/VP16 for 92% of patients in the R
group and 93% of those in the no R (NR) group. The content of
CD34 cells in the apheresis product was measured by ﬂow
cytometry using the ISHAGE method, and engraftment was re-
corded based on IBMTR criteria. Results: The average number
( SD) of CD34 cells collected in the entire study was 9.2 
106/kg  1.36 in a median of 2 days of apheresis. There were no
differences in the content of CD34 cells collected in patients who
received R (9.9  1.5  106 CD34 cells/kg) versus NR (9  1 
106 CD34 cells/kg), and no differences in the CD34 cells
collected from HL (10.6  11  106 CD34 cells/kg ) versus
NHL patients (8.6  13  106 CD34 cells/kg). Two patients in
the NR arm required 2 mobilizations versus none in the R arm.
Neutrophil engraftment was equal between the R and NR groups
with median 13 days versus 12 days, respectively, as was platelet
engraftment (median, R  19 days vs NR  22 days). With a
medium follow-up of 1 year, there is no difference in survival in
patients treated with (91%) or without R (88%). Conclusion:
Rituximab during the mobilization regimen did not have adverse
effects on HPC collection, neutrophil or platelet engraftment after
autologous transplantation in patients with relapsed/refractory HL
or NHL. The effect of including rituximab during HPC mobili-
zation on event-free survival in autologous HPCT warrants eval-
uation in phase 3 trials.
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PEGFILGRASTIM ALONE SUCCESSFULLY MOBILIZES PERIPHERAL
CD34 CELLS IN CHEMOTHERAPY NAIVE SUBJECTS WITH SOLID
TUMORS: INITIAL RESULTS OF A PHASE 1–2 STUDY
Pettengell, R.1, Willis, F.1, Woll, P.J.2 4, Desborough, C.3, Buchanan,
K.3 1. Department of Haematology, St. George’s Hospital Medical
School, London, United Kingdom; 2. Cancer Research Centre, Weston
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